Antipyrine and doxycycline pharmacokinetics in patients with thyroid disorders.
Pathological conditions are known to affect pharmacokinetics of many drugs. Antipyrine half-life is used as a marker of liver microsomal enzyme function. Antipyrine pharmacokinetics, therefore, was investigated in 23 thyrotoxic and 11 euthyroid goitre patients. Of these, 11 thyrotoxic and 9 euthyroid goitre patients also participated in doxycycline bioavailability studies. In thyrotoxic patients, antipyrine half-life and AUCo infinity and doxycycline Cpmax and AUCo infinity were found to be reduced as compared to those of healthy euthyroid normal subjects. Following treatment of thyrotoxicosis, the antipyrine half-life and AUCo infinity returned to normal. Doxycycline AUCo infinity returned to near normal range but Cpmax did not.
Nayak
V K
VK
Department of Pharmacology, Seth G.S. Medical College, Parel, Bombay, Maharashtra.
Desai
N K
NK
Kshirsagar
N A
NA
Bhandarkar
S D
SD
Satoskar
R S
RS
D000284:Administration, Oral; D000328:Adult; D000983:Antipyrine / Q000493:pharmacokinetics*; D001682:Biological Availability; D004318:Doxycycline / Q000493:pharmacokinetics*; D005260:Female; D006042:Goiter / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D013971:Thyrotoxicosis / Q000378:metabolism*
D004318:Doxycycline; D000983:Antipyrine